VENTANA MMR RxDx Panel
A four-stain test that shows whether a womb cancer has lost its DNA spell-checker, which makes immunotherapy likely to work.
Overview
Approved by the FDA in August 2021 together with dostarlimab for mismatch-repair-deficient (dMMR) recurrent or advanced endometrial cancer, the first immunohistochemistry companion diagnostic for mismatch-repair status. MMR immunohistochemistry is cheap, fast and available in every pathology laboratory, and is the recommended first-line test in endometrial and colorectal cancer, where it also serves as universal screening for Lynch syndrome. Where results are equivocal, PCR or NGS-based microsatellite-instability testing is used. Immunotherapy responses in dMMR tumours are among the most durable in oncology, so the stain has outsized consequences for a patient.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Companion diagnostic for dostarlimab in dMMR endometrial cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- What a result means: loss of one or more MMR proteins (dMMR) means checkpoint immunotherapy is an option and that inherited Lynch syndrome should be considered; intact staining (pMMR) means other treatments come first.
Latest papers
topQuery for this drug: (TITLE:"VENTANA MMR RxDx Panel" OR ABSTRACT:"VENTANA MMR RxDx Panel" OR TITLE:"VENTANA MMR RxDx" OR ABSTRACT:"VENTANA MMR RxDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VENTANA MMR RxDx Panel, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductVENTANA PD-L1 (SP263) Assay
Shares Companion diagnostics, Histopathology & immunohistochemistry, Roche / Genentech and the tag test.
- ProductVENTANA PD-L1 (SP142) Assay
Shares Companion diagnostics, Histopathology & immunohistochemistry, Roche / Genentech and the tag test.
- ProductPD-L1 IHC 22C3 pharmDx
Shares Companion diagnostics, Histopathology & immunohistochemistry, Pembrolizumab and the tag test.
- ProductHER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)
Shares Companion diagnostics, Histopathology & immunohistochemistry, Roche / Genentech and the tag test.
- Productcobas EGFR Mutation Test v2
Shares Companion diagnostics, Roche / Genentech and the tag test.
- ProductTruSight Oncology Comprehensive
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Companion diagnostics and the tag test.
- ProductMI Cancer Seek
Shares Companion diagnostics, Colorectal cancer and the tag test.
- ProductTempus xT CDx
Shares Companion diagnostics, Colorectal cancer and the tag test.